SCHEMBL1778308

SCHEMBL1778308

CO[C@H]1O[C@H](COS(=O)(=O)c2ccc(C)cc2)[C@@H](O)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 4/20 0.44
LGALS9 O00182 3/20 0.44
SSTR5 P35346 2/20 0.44
SSTR1 P30872 1/20 0.44
SSTR2 P30874 1/20 0.44
SSTR4 P31391 1/20 0.44
SSTR3 P32745 1/20 0.44
BCHE P06276 1/20 0.42
FGF1 P05230 2/20 0.41
FGF2 P09038 2/20 0.41
VEGFA P15692 2/20 0.41
HPSE Q9Y251 2/20 0.41
LGALS8 O00214 1/20 0.41
LGALS4 P56470 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
SLC6A2 P23975 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13224917 0.88 FGF1 (0.40) LGALS3LGALS9SSTR5BCHEFGF1
SCHEMBL13224946 0.88 TACR1 (0.41) LGALS3LGALS9SSTR5SSTR1SSTR2
SCHEMBL14890384 0.85 FGF1 (0.44) LGALS9FGF1FGF2VEGFAHPSE
SCHEMBL1775668 0.85 NT5E (0.47) LGALS3LGALS9SSTR5SSTR1SSTR2
SCHEMBL28316892 0.84 FGF1 (0.52) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL28315418 0.81 FGF1 (0.41) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL1777182 0.81 LMNA (0.36) FGF1FGF2VEGFAHPSECA1
SCHEMBL1777185 0.81 LMNA (0.36) FGF1FGF2VEGFAHPSECA1
SCHEMBL7150973 0.80 CA9 (0.46) FGF1CA1CA2CA9
SCHEMBL7154401 0.80 CA9 (0.46) FGF1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 US disclosed
EP-1589023-A1 OLIGOSACCHARIDE DERIVATIVE Sankyo Company, Limited (JP) 2005-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A LGALS3 577/4885LGALS9 561/4885SSTR5 1065/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 LGALS3 197/4885LGALS9 174/4885SSTR5 452/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 LGALS3 197/4885LGALS9 174/4885SSTR5 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.